TY - JOUR
T1 - Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease
T2 - A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group
AU - Verberne, Wouter R.
AU - Das-Gupta, Zofia
AU - Allegretti, Andrew S.
AU - Bart, Hans A.J.
AU - van Biesen, Wim
AU - García-García, Guillermo
AU - Gibbons, Elizabeth
AU - Parra, Eduardo
AU - Hemmelder, Marc H.
AU - Jager, Kitty J.
AU - Ketteler, Markus
AU - Roberts, Charlotte
AU - Al Rohani, Muhamed
AU - Salt, Matthew J.
AU - Stopper, Andrea
AU - Terkivatan, Türkan
AU - Tuttle, Katherine R.
AU - Yang, Chih Wei
AU - Wheeler, David C.
AU - Bos, Willem Jan W.
N1 - Funding Information:
Wouter R. Verberne, MD, MSc, Zofia Das-Gupta, PhD, Andrew S. Allegretti, MD, MSc, Hans A.J. Bart, MSc, Wim van Biesen, MD, PhD, Guillermo García-García, MD, Elizabeth Gibbons, MSc, Eduardo Parra, MD, PhD, Marc H. Hemmelder, MD, PhD, Kitty J. Jager, MD, PhD, Markus Ketteler, MD, PhD, Charlotte Roberts, MBBS, BSc, Muhamed Al Rohani, MD, Matthew J. Salt, MSc, Andrea Stopper, PhD, Türkan Terkivatan, MD, PhD, Katherine R. Tuttle, MD, Chih-Wei Yang, MD, David C. Wheeler, MD, and Willem Jan W. Bos, MD, PhD., This project was made possible by funding to ICHOM from the Agency for Clinical Innovation, Australia; Providence Health and Services, United States of America; European Renal Care Providers Association, Belgium; Santeon (Hospital Group), the Netherlands; and the Dutch Kidney Foundation, the Netherlands. The funders played no role in the study design; collection, analysis, or interpretation of the data; writing of the report; or the decision to submit the article for publication., Dr Allegretti has received consulting fees from Ferring Pharmaceuticals and grant support from the American College of Gastroenterology. Mr Bart has received lecture fees from speaking at the invitation of Baxter and travel support from Diaverum. Ms Gibbons was funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care Oxford at Oxford Health National Health Service Foundation Trust. Dr Jager has received grant support from the ERA-EDTA and the European Union. Ms Roberts has received travel support and lecture fees from speaking at the invitation of Fresenius Medical Care. Dr Stopper has stock options in Fresenius Medical Care and receives salary as an executive employee of Fresenius Medical Care. Dr Tuttle has received consulting fees from Eli Lilly & Co, Astra Zeneca, Boehringer Ingelheim, and Gilead; travel support from Eli Lilly & Co; and grant support from the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health and Providence Health and Services. Dr Wheeler has received consulting fees from Amgen, Akebia, AstraZeneca, Janssen, Vifor Fresenius, Reid Elsevier, Kyowa Kirin, and Bayer and lecture fees from Amgen. Drs Verberne and Bos have received grant support from the Dutch Kidney Foundation and Zilveren Kruis Health Insurance. The remaining authors declare that they have no revelant financial interests., We thank all patients and external stakeholders for their time and effort in contributing to the patient advisory group and online review surveys., A summary of this work was presented in poster form at American Society of Nephrology Kidney Week 2017 (October 31-November 5, 2017; New Orleans, LA)., Received May 24, 2018. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, and a Deputy Editor. Accepted in revised form October 14, 2018.
Publisher Copyright:
© 2018 The Authors
PY - 2019/3
Y1 - 2019/3
N2 - Value-based health care is increasingly promoted as a strategy for improving care quality by benchmarking outcomes that matter to patients relative to the cost of obtaining those outcomes. To support the shift toward value-based health care in chronic kidney disease (CKD), the International Consortium for Health Outcomes Measurement (ICHOM) assembled an international working group of health professionals and patient representatives to develop a standardized minimum set of patient-centered outcomes targeted for clinical use. The considered outcomes and patient-reported outcome measures were generated from systematic literature reviews. Feedback was sought from patients and health professionals. Patients with very high-risk CKD (stages G3a/A3 and G3b/A2-G5, including dialysis, kidney transplantation, and conservative care) were selected as the target population. Using an online modified Delphi process, outcomes important to all patients were selected, such as survival and hospitalization, and to treatment-specific subgroups, such as vascular access survival and kidney allograft survival. Patient-reported outcome measures were included to capture domains of health-related quality of life, which were rated as the most important outcomes by patients. Demographic and clinical variables were identified to be used as case-mix adjusters. Use of these consensus recommendations could enable institutions to monitor, compare, and improve the quality of their CKD care.
AB - Value-based health care is increasingly promoted as a strategy for improving care quality by benchmarking outcomes that matter to patients relative to the cost of obtaining those outcomes. To support the shift toward value-based health care in chronic kidney disease (CKD), the International Consortium for Health Outcomes Measurement (ICHOM) assembled an international working group of health professionals and patient representatives to develop a standardized minimum set of patient-centered outcomes targeted for clinical use. The considered outcomes and patient-reported outcome measures were generated from systematic literature reviews. Feedback was sought from patients and health professionals. Patients with very high-risk CKD (stages G3a/A3 and G3b/A2-G5, including dialysis, kidney transplantation, and conservative care) were selected as the target population. Using an online modified Delphi process, outcomes important to all patients were selected, such as survival and hospitalization, and to treatment-specific subgroups, such as vascular access survival and kidney allograft survival. Patient-reported outcome measures were included to capture domains of health-related quality of life, which were rated as the most important outcomes by patients. Demographic and clinical variables were identified to be used as case-mix adjusters. Use of these consensus recommendations could enable institutions to monitor, compare, and improve the quality of their CKD care.
KW - case-mix adjustment
KW - Chronic kidney disease (CKD)
KW - dialysis
KW - health-related quality of life (HRQoL)
KW - kidney transplantation
KW - modified Delphi technique
KW - outcome assessment
KW - patient reported outcome measures (PROMs)
KW - patient-centered outcomes
KW - quality of health care
KW - routine clinical practice
KW - shared decision making
KW - value-based health care (VBHC)
UR - http://www.scopus.com/inward/record.url?scp=85058624982&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2018.10.007
DO - 10.1053/j.ajkd.2018.10.007
M3 - Article
C2 - 30579710
AN - SCOPUS:85058624982
SN - 0272-6386
VL - 73
SP - 372
EP - 384
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3
ER -